Quinoline derivatives as NK3 anatgonists

Details for Australian Patent Application No. 2006253054 (hide)

Owner AstraZeneca AB

Inventors Alhambra, Cristobal; Albert, S. Jeffrey; Simpson, R. Thomas; Kang, James; Li, Yan; Woods, M James; Koether, M. Gerard

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2006253054

PCT Pub. Number WO2006/130080

Priority 60/687,418 03.06.05 US

Filing date 30 May 2006

Wipo publication date 7 December 2006

International Classifications

A61K 31/47 (2006.01) - Quinolines

A61P 3/04 (2006.01) Drugs for disorders of the metabolism

A61P 25/18 (2006.01) Drugs for disorders of the nervous system

A61P 25/24 (2006.01) Drugs for disorders of the nervous system

C07D 215/52 (2006.01) Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems

Event Publications

6 December 2007 PCT application entered the National Phase

  PCT publication WO2006/130080 Priority application(s): WO2006/130080

20 January 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006253056-A peptide ligand to impair cancer cell migration

2006253049-Novel MCHR1 antagonists and their use for the treatment of MCHR1 mediated conditions and disorders